Intellia Therapeutics, Inc.
NTLA Healthcare Biotechnology
Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024. In the quarter to June 2026, revenue fell 46.2%, EPS grew 18.4% and free cash flow grew 15.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NTLA
Intellia Therapeutics, Inc. (NTLA) EV/Sales
As of 16 October 2026, Intellia Therapeutics, Inc. (NTLA) trades at a EV/Sales of 18.3×. Over the past ten years it has ranged from −7.5× (May 2016) to 351× (November 2021); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.7× | (18.61%) |
| FY2024 | 9.5× | (81.59%) |
| FY2023 | 51.7× | 66.19% |
| FY2022 | 31.1× | (86.53%) |
| FY2021 | 231× | 447.07% |
| FY2020 | 42.2× | 340.18% |
| FY2019 | 9.6× | 6.59% |
| FY2018 | 9.0× | (45.83%) |
| FY2017 | 16.6× | 933.36% |
| FY2016 | 1.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 30.6× | 76.92% |
| Mar 2026 | 17.3× | 123.17% |
| Dec 2025 | 7.7× | (67.97%) |
| Sep 2025 | 24.2× | 149.12% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. | 18.3× |
| OCUL Ocular Therapeutix, Inc. compare | 19.6× |
| QURE uniQure N.V. compare | 36.8× |
| STOK Stoke Therapeutics, Inc. compare | 47.2× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)